Results 251 to 260 of about 60,894 (286)
Some of the next articles are maybe not open access.
Immunogenicity of pneumococcal conjugate vaccines
The Pediatric Infectious Disease Journal, 2000Prevention of pneumococcal infections is a public health priority because of the high impact of the disease and because of the increasing problems due to antimicrobial resistance. Traditional vaccines, consisting of purified capsular polysaccharides (PSs) of Streptococcus pneumoniae, are not immunogenic in young children.
openaire +3 more sources
Conjugate pneumococcal vaccines: an overview
Medical Journal of Australia, 2000A seven-valent conjugate pneumococcal vaccine has been shown to have dramatic efficacy against invasive pneumococcal disease and lesser efficacy against otitis media and pneumonia. This vaccine was licensed for use in infants in the United States in February 2000 and is recommended there for routine use in infants and catch-up vaccination in high-risk ...
openaire +3 more sources
Impact of the Conjugate Pneumococcal Vaccine in Arkansas
Pediatric Infectious Disease Journal, 2004On the basis of the success of the early trials in the prevention of invasive pneumococcal disease in infants and children using a heptavalent conjugate pneumococcal vaccine, the American Academy of Pediatrics recommended in August 2000 that the vaccine be given concurrently with other childhood immunizations.Data concerning invasive pneumococcal ...
Nancy C. Tucker +2 more
openaire +2 more sources
Pneumococcal Conjugate Vaccines
1995The development of multivalent pneumococcal vaccines for the prevention of both systemic and noninvasive pneumococcal diseases in infants, older adults, and immunecompromised individuals has gained increasing importance over the last decade. The rising cost of medical care has renewed interest in prevention instead of cure for a disease and in many ...
openaire +3 more sources
Clinical Infectious Diseases, 2018
BACKGROUND A notable reduction of the pneumococcal disease burden among adults was observed after the introduction of a 7-valent pneumococcal conjugate vaccine (PCV7) in childhood immunization programs. In 2010, a 13-valent pneumococcal conjugate vaccine
N. Vadlamudi, Anna Chen, F. Marra
semanticscholar +1 more source
BACKGROUND A notable reduction of the pneumococcal disease burden among adults was observed after the introduction of a 7-valent pneumococcal conjugate vaccine (PCV7) in childhood immunization programs. In 2010, a 13-valent pneumococcal conjugate vaccine
N. Vadlamudi, Anna Chen, F. Marra
semanticscholar +1 more source
Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation [PDF]
European Journal of Clinical Microbiology & Infectious Diseases, 2007 The French Pediatric Infectious Diseases Group set up an active surveillance network to analyze the clinical and biological features of pneumococcal meningitis and the impact of the seven-valent pneumococcal conjugate vaccine (PCV7). From 2001 to 2005, 234 pediatric wards working with 166 microbiology laboratories enrolled all children with ...
P. d'Athis +7 more
openaire +2 more sources
Pneumococcal conjugated vaccine: PHiD-CV
Expert Review of Anti-infective Therapy, 2009At the beginning of a new century, we have gained significant achievements against pneumococcal infections by using conjugated pneumococcal vaccines. In January 2009, the EMEA issued a positive opinion about, and recommended the approval of, GlaxoSmithKline's pediatric pneumococcal candidate vaccine, which is indicated for active immunization against ...
Zeynel Abidin Yargic +1 more
openaire +2 more sources
Pharmacoeconomics of Pneumococcal Conjugate Vaccines
2014This chapter reviews key concepts in pharmacoeconomics and the pharmacoeconomic literature pertaining to pneumococcal conjugate vaccine (PCV), with an emphasis on recent work and future advances. A cost minimization analysis assumes that all interventions being analyzed result in equal health outcomes and that the primary consideration is which ...
Anushua Sinha, G. Thomas Ray
openaire +2 more sources
20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults
Drugs, 2022M. Shirley
semanticscholar +1 more source
Correlates of immunity for pneumococcal conjugate vaccines
Vaccine, 2003The purpose of the NIAID/FDA joint workshop, "correlates of immunity for pneumococcal conjugate vaccines (PCVs)," was to discuss the present understanding of protective immunity against invasive pneumococcal disease and identify in vitro measures that may represent immunologic correlates in future clinical trials.
Lucia H. Lee +4 more
openaire +2 more sources